Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Fovea is in breach of its obligations under Sections 3.9.1, 3.9.2 or 3.9.3, then CombinatoRx shall so notify Fovea in writing, specifying the basis for its belief, and the Parties shall meet within thirty (30) days after such written notice to discuss in good faith for a period of not more than twenty-one (21) days CombinatoRx's concerns and Fovea's development plans with respect to the Collaboration Combinations.
Notification and Meeting. If at any time AstraZeneca has a reasonable basis to believe that Flexion is in breach of its obligations under Section 5.3 with respect to a Major Market, then AstraZeneca shall so notify Flexion, specifying the basis for its belief, and the Parties shall meet […***…] after such notice to discuss in good faith AstraZeneca’s concerns and Flexion’s Development and commercialisation plans with respect to the Licensed Product(s) to attempt to eliminate AstraZeneca’s concerns.
Notification and Meeting. If at any time NovaDel has a reasonable basis to believe that Licensee is in breach of its obligations under Article 3.8 with respect to a country in the Territory, NovaDel shall notify Licensee thereof, specifying the basis for its belief, and the Parties shall meet within ten (10) days after such notice to discuss in good faith NovaDel's concerns and Licensee's activities with respect to the Licensed Products in such country.
Notification and Meeting. If at any time a Party has a reasonable basis to believe that the other Party (the “Pursuing Party”) is in material breach of a material obligation under Section 4.12.1 with respect to a Collaboration Antigen or Discontinued Antigen, as applicable, then the non-Pursuing Party shall so notify the Pursuing Party, specifying the basis for its belief, and the Parties shall meet within [Confidential treatment requested] after such notice to discuss in good faith the non-Pursuing Party’s concerns and the Pursuing Party’s development and commercialization plans with respect to such Antigen.
Notification and Meeting. If either party learns that a third party (the "Infringer") is:
(a) filing with the United States Food and Drug Administration ("FDA"), or foreign counterpart, an Abbreviated New Drug Application (or foreign equivalent) on a product that infringes a PATENT CLAIM, which application contain the certification described in 21 U.S.C 355 (j)(2)(A)(vii)(IV);
(b) filing with the FDA an NDA seeking approval to market and SELL a product that infringes a PATENT CLAIM;
Notification and Meeting. If at any time Dynavax has a reasonable basis to believe that AstraZeneca is in material breach of its material obligations under Section 8.10, then Dynavax shall so notify AstraZeneca, specifying the basis for its belief, and the Parties shall meet within [ * ] days after such notice to discuss in good faith Dynavax’s concerns and AstraZeneca’s Development and Commercialisation plans with respect to any CD, the Product or any Combination Product.
Notification and Meeting. If at any time Avanir has a reasonable basis to believe that AstraZeneca is in breach of its material obligations under Section 8.1, then Avanir shall so notify AstraZeneca, specifying the basis for its belief, and the Parties shall meet within thirty (30) days after such notice to discuss in good faith Avanir's concerns and AstraZeneca's development and commercialisation plans with respect to the Licensed Compound and Licensed Product.
Notification and Meeting. If at any time CombinatoRx has a reasonable basis to believe that Angiotech is in breach of its material obligations under Section 7.2, then CombinatoRx shall so notify Angiotech in writing, specifying the basis for its belief, and the Parties shall meet within thirty (30) days after such written notice to discuss in good faith for a period of not more than twenty-one (21) days CombinatoRx's concerns and Angiotech's development and commercialization plans with respect to the Licensed Compound and Licensed Product.
Notification and Meeting. If at any time AstraZeneca has a reasonable basis to believe that Neoprobe is in breach of its obligations under Section 5.2 with respect to a Major Market, then AstraZeneca shall so notify Neoprobe, specifying the basis for its belief, and the Parties shall meet within thirty (30) days after such notice to discuss in good faith AstraZeneca’s concerns and Neoprobe’s development and commercialisation plans with respect to the Licensed Product. Confidential Treatment – Asterisked material has been omitted and filed separately with the Securities and Exchange Commission pursuant to a request for confidential treatment.
Notification and Meeting. Before the City or the Township may undertake any legal or equitable action pursuant to or to enforce any provision of this Agreement, that party shall first notify in writing the other party of the basis for the claim, including detailed recitations of the facts and the law upon which the claiming party is relying. The party receiving such a claim letter shall, within 21 days of receiving the claim, respond in writing identifying those issues on which there is agreement and stating in detail the facts and law upon which the responding party is relying. The parties shall schedule a meeting to occur within 14 days after the date the response is due to discuss and seek to resolve the dispute. These time frames may be adjusted with the written consent of the parties.
